The Food and Drug Administration could extend eligibility for Belviq to lower-risk patients, the agency says a popular gout drug raises cardiovascular risk, an AHA statement targets CV risk factors in children, and a class action suit against the American Board of Internal Medicine over MOC gets financial support from doctors.